Navigation Links
Ventana receives FDA clearance for Estrogen Receptor (ER) Image Analysis and Digital Read Application for breast cancer
Date:12/5/2013

TUCSON, Ariz., Dec. 5, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Companion Algorithm ER (SP1)1 image analysis algorithm used with the VENTANA iScan Coreo scanner running Virtuoso2 software.  With this clearance, Ventana is now the only company in the industry offering a comprehensive portfolio of FDA-cleared image analysis algorithms and digital read applications for the five key immunohistochemistry (IHC) breast markers.  

(Photo:  http://photos.prnewswire.com/prnh/20131205/LA28038)

There are two intended uses obtained with the 510(k) clearance for ER:  first, clinical use of the software algorithm to semi-quantify the ER biomarker, and second, digital read, or clearance to manually read and score the ER biomarker using a computer monitor, in lieu of a microscope. This means the pathologist will be able to digitally view a slide on a computer monitor, assign a score, and then sign out the case with a diagnosis or opinion, with or without the assistance of an image analysis algorithm. 

All IHC breast markers in the Ventana portfolio have both image analysis and digital read application FDA 510(k) clearances. Along with the Companion Algorithm ER (SP1) image analysis software, the full breast panel includes HER2 (4B5), PR (1E2), Ki-67 (30-9) and p53 (DO-7) image analysis algorithms along with their accompanying VENTANA IHC assays3.

"The biomarkers, scanner, and image analysis software have been optimized and clinically validated to work together as a system.  Not only does this provide a powerful image analysis tool but an added level of clinical confidence," says Robert C. Babkowski MD, FCAP Chair, Department of Pathology and Laboratory Medical Director, The Stamford Hospital.

"This most recent addition of the VENTANA ER (SP1) Companion Algorithm software to our digital pathology portfolio demonstrates our continued commitment to provide our customers with the most advanced, clinically validated, pathology solutions available," says Dr. Steve Burnell, Vice President, Ventana Digital Pathology and Workflow. "It represents another significant step by Ventana in assisting pathologists with the consistent and objective interpretation of these important breast cancer biomarkers, supporting the highest standards of patient care."

Hormone receptor status is a main factor in planning breast cancer treatment.  The presence or absence of estrogen receptor (ER) and progesterone receptor (PR) status in cancer cells, along with HER2 receptor status, help guide treatment options. The Ki-67 protein test and p53 genetic mutation test are known to be excellent markers for cellular proliferation.

"Digital pathology is a transformational technology, delivering greater accessibility, confidence and faster results to physicians and their patients," says Ventana President Mara G. Aspinall.

1 When the VENTANA ER (SP1) algorithm is used in conjunction with the CONFIRM anti-ER (SP1) Rabbit Monoclonal Primary Antibody test, it may be used as an aid in the assessment of ER status in breast cancer patients for whom endocrine treatment is being considered but is not the sole basis for treatment. 

2 Virtuoso software is part of a 510(k)-cleared system with the HER2 (4B5), PR (1E2), Ki-67 (30-9), ER (SP-1) and p53 (DO-7) Companion Algorithm image analysis software. The FDA clearance includes all of the components of the VENTANA laboratory workflow solution including the company's BenchMark IHC/ISH slide stainer, exclusive HER2 (4B5), PR (1E2), ER (SP1), and Ki-67 (30-9) clones, detection systems, iScan slide scanner, and Virtuoso software.

3 The PATHWAY HER2 (4B5) assay is FDA-approved, the CONFIRM PR (1E2) and CONFIRM ER (SP1) assays are FDA-cleared, and Ki-67 (30-9) and p53(DO-7) assays are FDA class 1, exempt in vitro diagnostics.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare  through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

CONFIRM, VENTANA, the VENTANA logo, VIRTUOSO, ISCAN, PATHWAY, and BenchMark are trademarks of Roche.

Visit http://ventana.com/ to learn more.

VMSI Media Relations

Jacqueline Bucher

Senior Director, Corporate Communications

Phone: 520-877-7288

e-mail: Jacquie Bucher


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
2. Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers
3. UCSB professor receives award for graphene electronics research
4. Watsons Generic Yaz(R) Receives FDA Approval
5. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
6. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Intimate Bridge 2 Conception, Inc. Receives $4.3M
9. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
10. BioNeutral Group Receives $400,000 in Equity Financing
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... June 22, 2016  Mesa Biotech Inc., a ... testing platform designed specifically for point-of-care (POC) infectious ... scientific advisory board (SAB). Approved by the executive ... is chartered to advise on the development and ... Led by Dr. Steve Young , this ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):